Investors
Shaping the Future of Aesthetics & Tissue Reconstruction
Revolutionizing billion-dollar markets in facial rejuvenation, body contouring, and tissue repair.
GLOBAL MARKET
One New Technology
Multi Billion-Dollar Markets
$1.8B
Global Tissue Biologicslink
$1.2B
Cosmetic Biostimulatorylink
“BOTOX”
$2.7B / Year Product
In aesthetics single products like “Botox” can become multi-billion dollar brands.link
Just as Botox transformed a niche neurotoxin into a billion-dollar blockbuster, Conexeu’s patented, collagen platform could ignite the next multi-billion-dollar wave in regenerative aesthetics—an opportunity for investors to enter before the category is fully defined.
Unmet Global Need
Global aesthetics lacks innovation in safe regenerative volumizers and commercial therapies inadequately address new problems.
Groundbreaking Research
Groundbreaking translational and clinical research validates Conexeu’s regenerative collagen gel across multiple aesthetic applications.
Pioneering Technology
A collagen-based platform enabling on-demand formation of functional tissues.
Industry Timing
The time has arrived for a next-generation collagen gel addressing needs in aesthetics and tissue repair.
The 30-Second Thesis
Big Companies Don’t Invent Revolutions; Innovators Do.
Microsoft bought OpenAI access, Meta bought Instagram, and Merz, Allergan, and Galderma buy every breakthrough filler they can’t create fast enough.
Global Investors Seek Innovation in Aesthetics
“I would love to see more injectable innovation that we could buy or partner with…”
– Michael Keyoung -C Bridge Capital $7.6B AUM, 7th largest P.E. firm in Asia
$1.2B investment in Hugel Aesthetics*
It’s Time for a Change
Conexeu’s innovative collagen gel is being developed to address the multi- billion+* dermal filler segment, with the goal of creating a new category of regenerative aesthetics.
READY FOR INNOVATION
Dermal Fillers are Aging
The average dermal filler was introduced about the same time that Blackberry® was cutting-edge technology.
26 Yrs.
EU Approved 1999
19 Yrs.
FDA Approved 2006
22 Yrs.
FDA Approved 2003
19 Yrs.
FDA Approved 2006
The aesthetic market is using BlackBerry-era tech. The top fillers still dominate — with chemistries invented before the iPhone even existed.
Aesthetics needs iPhone-level performance. Conexeu’s opportunity is now – developing smarter, regenerative solutions.
Patented, Scalable Platform
Conexeu, 3–5 years ahead of global aesthetic pharma for a new bio-stimulatory collagen gel.
Conexeu’s Human Collagen-based formula is a non-toxic, non-inflammatory injectable with regenerative properties that creates new tissue. From small facial lines to large-volume body contouring, this scaffold-based system may be poised to transform not just aesthetics, but also reconstructive medical fields.
Conexeu Mission
The Time Has Arrived
At Conexeu, we’re not just introducing another filler; we’re igniting a paradigm shift in how aesthetics approaches tissue restoration.
Consumers Are Driving the Market
Consumers Want More Collagen
67%
of research shows* consumers would consider
non-surgical aesthetic treatments
that naturally stimulates collagen production.
Consumers Crave Innovation in Aesthetics
30%
of consumers were triggered to get filler treatments due to new/innovative filler product.*
Aging Well, Not Just Anti-Aging
82%
of customers are focused on looking healthy vs. looking young*. Globally, anti-aging and aesthetic treatments have experienced exponential growth with a focus on Collagen replenishment.
(*See “Future of Aesthetics” Allergan Aesthetics Global Survey 2021)link
COLLAGEN IP
CXU™ Natural — Non-Toxic and Regnerative
The time is right for creating a new category of regenerative aesthetics—from precise soft-tissue refinement to large-volume contouring.
IMPACT on Aesthetics
Did #OZEMPIC Just Open a Massive New Market for Facial Fillers?
One of the most significant trends in plastic surgery today is the rise of “GLP-1” medications like Ozempic and Wegovy*.
$126B
Global GLP-1 sales forecast by 2029, 30% CAGR*
44%
U.S. Market Share*
GLP-1 Drugs “OZEMPIC” are Driving Global Consumers into Aesthetic Treatments
GLP-1 drugs can trigger aggressive weight loss, stripping facial fat faster than skin can adapt. Bringing new aesthetic challenges, such as sagging skin and facial volume loss —commonly referred to as “Ozempic Face” and “Ozempic Body”.
#OzempicFace describes the hollowed cheeks, loose skin and premature wrinkles that can appear after weight loss.
62%
of consumers who lost weight with GLP-1 medications are now seeking treatments to address loose or sagging skin. This is growing demand for skin tightening and body contouring treatments globally.
GLOBAL MARKET DRIVER
Market Reality — Few Players, Massive Void
Conexeu is focusing on the huge demand GLP-1–induced aggressive facial fat-loss has created for new facial filler demand. (“#OzempicFace”).
CXU™ is an investigational biostimulatory collagen gel, being evaluated as a potential option to address GLP-1–related skin laxity by supporting tissue volume restoration.
Regeneration – The Next Global Market for Value Generation.
CXU™ isn’t just “another filler”—it’s striving to create an entirely new regenerative-aesthetics category.
Conexeu – The Next Generation.
-
Regenerative Collagen Hydro-Gel – CXU™ is a patented, temperature-gelling scaffold designed to support native tissue growth rather than simply “fill” space.
-
Single-Platform, Multi-Market Pipeline – Our one CXU™ formulation is being investigated for multiple billion-dollar applications: injectable facial fillers, large-volume body contouring, tissue reconstruction and repair.
-
Streamlined U.S. Regulatory Plan – Tissue repair targets a 510(k) pathway; aesthetic indications follow under the same formulation, reducing incremental complexity and cost.
-
Global IP Estate – Issued patents in the United States, Japan, Europe, and Australia, plus pending claims in Canada, secure freedom to operate and partnering leverage.
-
Deep Technical Moat – twelve years of university-backed R&D and eleven peer-reviewed papers underpin the scaffold’s biocompatibility and bio-stimulatory profile.
-
Multi-Billion-Dollar TAM – If cleared, CXU™ could enter high-growth markets spanning $1.3B+ bio-stimulatory fillers, $10B injectable fillers, $6B advanced wound care, and large body application potential.
-
Seasoned Leadership & Scientific Bench Strength – World-renowned aesthetic surgeon, tissue-engineering PhDs, former CEOs/CMOs of global aesthetics leaders, device veterans with proven FDA-clearance track records.
Conexeu may have the most innovative approach to collagen-based regenerative aesthetics today.
(Collagen) x (You) = CXU™
1.
Patented Human Collagen IP
Conexeu’s patented, investigational collagen scaffold targets wound care and aesthetics, offering a non-toxic gel designed to support tissue regeneration—opening multi-billion-dollar, high-margin markets versus conventional fillers or implants.
2.
Multiple High-Value Applications
CXU™ collagen gel targets multi-billion face, breast and butt contouring markets, with applications for volume restoration pending clearance—potentially driving value without requiring huge spending, for bigger returns.
3.
Robust M&A Landscape
The global aesthetic market has seen a surge in mergers and acquisitions, particularly for collagen protected IP. Conexeu’s proven research foundation and patents position the company as an attractive partner or acquisition target within the beauty and regenerative medicine space.
4.
Expert Team & Clinical Backing
Conexeu’s leadership comprises seasoned entrepreneurs, plastic surgeons, and regenerative medicine experts. A decade of R&D, multiple peer-reviewed publications, and ongoing R&D underscore the company’s readiness to disrupt the aesthetics sectors.
“Join Us in Shaping the Future of Regenerative Medicine”
At Conexeu, we’re not just introducing another filler or graft; we’re igniting a paradigm shift in how medicine approaches tissue restoration. From investors seeking high-growth opportunities to clinicians pursuing safer and more effective therapies—everyone benefits from a future driven by true regeneration.
Find Out More
Join our newsletter for regular updates on our progress
"*" indicates required fields